Physician profile
Robert Coleman Mceachern
NPI 1164413407
$5,197.13
in general payments reported to CMS, 2019-2025
37 companies · $836 in 2025
The $836 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,663 · 2020: $149 · 2021: $401 · 2022: $621 · 2023: $990 · 2024: $537 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $825.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Veran Medical Technologies, INC. | $651.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.48 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $610.03 | 2019-2025 | Tezspire, Fasenra, Imfinzi |
| Insmed, INC. | $271.77 | 2019-2024 | Arikayce |
| Sunovion Pharmaceuticals INC. | $239.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $207.12 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $150.02 | 2019-2025 | Zerbaxa, Recarbrio |
| Harmony Biosciences LLC | $138.10 | 2021-2025 | Wakix |
| Genzyme Corporation | $118.10 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $114.90 | 2023 | |
| Electromed, INC. | $97.15 | 2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $97.13 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $79.44 | 2019-2023 | |
| Philips North America LLC | $78.46 | 2019-2024 | (Ak6) Vest Therapy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.07 | 2021-2024 | Glassia |
| Grifols USA, LLC | $62.37 | 2023-2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $54.78 | 2022-2024 | Acthar |
| Astellas Pharma US INC | $54.52 | 2019-2020 | |
| Amgen INC. | $52.86 | 2023-2025 | Tezspire |
| Ambu INC. | $51.75 | 2022-2025 | |
| Fisher & Paykel Healthcare INC | $51.20 | 2021-2025 | Fisher & Paykel Healthcare |
| Pulmonx Corporation | $49.44 | 2019-2023 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Medtronic, INC. | $44.00 | 2023 | Illumisite |
| Portola Pharmaceuticals, LLC | $39.81 | 2019 | |
| Genentech USA, INC. | $39.28 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $38.71 | 2019 | |
| Pfizer INC. | $34.45 | 2022-2024 | |
| Axsome Therapeutics, INC. | $33.58 | 2022-2025 | Sunosi |
| Mylan Specialty L.P. | $32.03 | 2021-2023 | Yupelri |
| 3b Medical, INC. | $31.86 | 2024-2025 | Luna |
| La Jolla Pharmaceutical Company | $26.03 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $24.79 | 2019 | |
| Shionogi INC | $24.20 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.32 | 2025 | Purified Cortrophin Gel |
| Aerin Medical INC. | $16.74 | 2022 | |
| Monaghan Medical Corporation | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mceachern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.